Clinical Trials

Scientists can learn a tremendous amount about dementia and the brain from the study of healthy individuals as well as those who have been diagnosed with memory disorders. At the Alzheimer’s Disease Research Center (ADRC), our research goals are not only to improve diagnosis, delay progression, and enhance the well-being of those with Alzheimer's disease, but also to learn more about the normal process of aging.

All of the research conducted at the ADRC takes place at our Upper East Side campus. Clinical studies currently under way at the ADRC include:

Our study looks at the ability of a drug (LY2062430 or solanezumab) to delay Alzheimer’s disease-related memory loss in older people who have elevated levels of amyloid or beta amyloid proteins in their brain but are not yet displaying symptoms of the disease. Scientists believe these proteins play a key role in development of AD-related memory loss.

We are looking for healthy participants between ages 65-85 who have a study partner who can provide information about the participant’s health, attend appointments, and assist with correctly taking study medication. There is no cost to participate and participants will be paid for certain clinical visits. For more information, contact Kelly Pun at 212-241-8329. Principal Investigator: Mary Sano, PhD; GCO#: 91-0208(0018) and 91-0208(0019); HSM#: 14-00067; ISMMS IRB approved through 03/17/2017.

This study investigates the safety, tolerability, and effectiveness of an insulin nasal spray administered to people with Alzheimer’s disease or mild cognitive impairment. Participants either receive the insulin nasal spray or a placebo nasal spray for 12 months; for the following six months, all participants receive the insulin nasal spray.

We are looking for volunteers who are 55 years of age or older, are diagnosed with mild cognitive impairment or Alzheimer’s disease, are fluent in English or Spanish, can attend all study visits, and have a study partner who can also attend all study visits. There is no charge for participation and we serve lunch at some visits. For more information, contact Michael Kinsella at 212-241-8329. Principal Investigator: Hillel T. Grossman, MD. GCO#: 91-0208(0017); HSM#: 13-00768; ISMMS IRB approved through 10/28/2016.

We are evaluating an investigational drug for patients with mild to moderate Alzheimer’s disease that may protect brain cells, resulting in improved memory. Participants receive the study drug or a placebo and participate in the study for about 14 months.

We are seeking women and men ages 55-85 with mild to moderate Alzheimer’s disease who have been receiving donepezil (Aricept®) treatment for at least six months and who have a study partner with whom they have regular contact and who can attend study visits. There is no charge for participation. For more information, contact Florence Lau at 212-241-8329. Principal Investigator: Amy Aloysi, MD. GCO#: 91-208 (20). HSM#: 14-00065; ISMMS IRB approved through 3/17/2017.

This study is looking at the safety and tolerability of a drug called AZD0530, which was developed as a cancer therapy. Participants will receive either the drug or a sugar pill for about two years.

We are looking for people ages 55-84 who have a diagnosis of mild Alzheimer’s disease (AD) and a study partner with whom they have regular contact and who can attend all study visits. Participation is compensated.

For more information, contact Samantha Nazi at 212-241-8329. Principal Investigator: Mary Sano, PhD; GCO#: 91-0208(21); HSM#: 15-00208; ISMMS IRB approved through 5/4/2017.

 

 

The Grape Seed Extract Study is assessing the effect of grape seed extract in people with Alzheimer’s to determine the safest and most effective dose. Grape seed extract is a natural product that has been shown in laboratory studies to block the formation of brain toxic proteins involved in Alzheimer’s disease. Participants will either receive the active compound or a placebo.

We are looking for older adults who are experiencing memory loss that may be due to Alzheimer’s disease, who are fluent in either English or Spanish, and who have someone who can act as a study partner. There is no charge to participants. For more information, contact Florence Lau at 212-241-8329. Principal Investigator: Hillel T. Grossman, MD. ISMMS PPHS approved through 6/30/2016. (GCO #09-0307)

Studies suggest that diabetes may cause or worsen memory problems in older adults. We are looking to compare memory functioning in older adults with diabetes and those without the disease.

We are recruiting individuals over age 50 from minority backgrounds—because this group is often at highest risk for diabetes and is frequently understudied—who are not experiencing severe memory problems. To learn more, contact Jorge Ginory-Perez at 718-584-9000 Ext. 1705. Principal Investigator: Corbett Schimming, MD. Study Sponsored by: The National Institute on Aging (NIA) of the National Institutes of Health. ISMMS GCO #84-119 HSM #14-01098; IRB approved through 01/26/2017.

This national study of healthy elders and those with memory problems examines how memory disorders affect cognitive abilities and daily functioning. For those willing to be followed on a yearly basis, we provide free memory and medical evaluations to both healthy elders over age 74 and those of any age who have been diagnosed with Alzheimer's disease or related diseases including Mild Cognitive Impairment. Participation does not include treatment.

For more information or to schedule an appointment, call 212-241-8329.

In addition to the above studies, the ADRC has several active studies that are no longer recruiting new participants. These are:

The purposes of this study are to examine two genes to see if they provide insight into someone’s likelihood of developing Alzheimer’s disease and (2) to test a drug called pioglitazone (AD-4833), which may slow the progress of Alzheimer’s disease in those who show no signs of the condition.

Principal Investigator: Judith Neugroschl, MD; GCO#: 13-1688; HSM#: 13-00720; ISMMS IRB approved through 11/18/2015.

This study is investigating the safety, tolerability, and efficacy of a medication, MK-8931, in patients with mild to moderate Alzheimer's disease. MK-8931 is hoped to slow progression of the disease.

Principal Investigator: Judith Neugroschl, MD; GCO# 13-0701; ISMMS IRB approved through 1/5/2016.